Alemtuzumab + Fludarabine + Melphalan

Alemtuzumab + fludarabine + melphalan is a reduced-intensity conditioning (RIC) regimen used in allogeneic hematopoietic stem cell transplantation (HSCT). This combination therapy is primarily used for patients with various hematological conditions including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), primary immune deficiencies, and severe aplastic anemia[1][3][5]. The regimen is notable for its effectiveness in reducing the incidence of acute and chronic graft-versus-host disease (GVHD) while maintaining reliable engraftment[4][5]. It's particularly valuable for patients who may not tolerate more intensive conditioning regimens, including those with comorbidities, decreased performance status, or advanced age[3]. ## Key Features and Benefits **Efficacy Profile:** - Provides reliable engraftment with minimal early transplant-related mortality in appropriate patients[4] - Particularly effective for patients with standard-risk leukemia (first or second complete remission) or MDS with <5% blasts[3] - Associated with low incidence of extensive chronic GVHD, especially with related donors[3][5] **Patient Selection:** - Suitable for patients with high-risk disease characteristics, comorbidities, and/or modest reduction in performance status[3] - Can be used across various age groups, including pediatric and young adult patients[1] **Chimerism Outcomes:** - May result in mixed chimerism (reported cumulative incidence of 46% in one study)[1] - Different risk profiles for mixed chimerism based on diagnosis subgroups and graft source[1] - Patients with marrow failure and SCID may experience less whole blood mixed chimerism[1] ## Administration Protocol The typical administration schedule includes: 1. **Alemtuzumab**: Administered on days -8 to -3 (various dosing schedules exist, including 100 mg total dose given as 20 mg on days -7 to -3, or alternative schedules of 60 mg or 50 mg)[5][8] 2. **Fludarabine**: Usually given at 30 mg/m² intravenously daily for 5 days (days -7 to -3 or days -6 to -2)[6][8] 3. **Melphalan**: Administered after fludarabine, typically on day -2[6][8] 4. **Supportive care**: Includes premedications (chlorphenamine, paracetamol), antiemetics (metoclopramide, ondansetron, aprepitant), antimicrobials, and hydration protocols[6][8] 5. **GVHD prophylaxis**: Often includes methotrexate post-transplant[6][8] ## Clinical Outcomes Studies have shown that this regimen: - Results in approximately 48% 1-year survival and 38% progression-free survival in high-risk AML/MDS patients[3] - Has a relapse rate of around 27% and treatment-related mortality of 33% in these populations[3] - Dramatically reduces the incidence of acute and chronic GVHD compared to regimens without alemtuzumab[5] - Performance score and disease status are major predictors of outcome[3] The regimen continues to be refined, with variations in alemtuzumab dosing being studied to optimize the balance between GVHD prevention and other outcomes[5].

Other names

Reduced-intensity conditioning (RIC) regimen